Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $83M invested in Lineage Cell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.39% more ownership
Funds ownership: 43.15% → 43.54% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $89.1M → $83M (-$6.06M)
Holders
115
Holding in Top 10
3
Calls
$15K
Puts
$1K
Top Buyers
| 1 | +$738K | |
| 2 | +$593K | |
| 3 | +$208K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$184K |
| 5 |
Barclays
London,
United Kingdom
|
+$174K |
Top Sellers
| 1 | -$825K | |
| 2 | -$766K | |
| 3 | -$234K | |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$164K |
| 5 |
Citigroup
New York
|
-$119K |